Mural Oncology plc Ordinary Shares

MURA

Mural Oncology plc is a biotechnology company focused on developing innovative cancer therapies. The company specializes in research and development initiatives aimed at improving treatment options for oncology patients. It leverages advanced scientific approaches to address unmet medical needs in the cancer treatment landscape.

$2.09 0.00 (0.00%)
🚫 Mural Oncology plc Ordinary Shares does not pay dividends

Company News

Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
Benzinga • Globe Newswire • October 24, 2025

Mural Oncology shareholders voted to approve an acquisition by XRA 5 Corp., a subsidiary of XOMA Royalty, with over 99% of votes cast in favor. The transaction values Mural at approximately $36.2 million and is expected to close in Q4 2025.

XOMAXOMAOXOMAP
$HAREHOLDER ALERT: The M&A Class Action Firm Reminds Shareholders of Upcoming Merger Deadlines – AMWD, PHLT, ARIS, and MURA
GlobeNewswire Inc. • Juan Monteverde • September 28, 2025

Law firm Monteverde & Associates is investigating merger activities for several companies, including American Woodmark, Performant Healthcare, Aris Water Solutions, and Mural Oncology, alerting shareholders about upcoming voting deadlines.

AMWDPHLTARIS
Mural Oncology (MURA) Q2 Loss Widens 49%
The Motley Fool • Na • August 4, 2025

Mural Oncology announced the complete discontinuation of all clinical programs, including its lead drug nemvaleukin alfa, and is now exploring strategic alternatives like sale or liquidation after experiencing significant financial losses.

Related Companies

Vanguard New York Tax-Exempt Bond ETF
MUNY
Murphy Oil Corp.
Murphy Oil Corp.
MUR
TCW Multisector Credit Income ETF
MUSE
MURPHY USA INC.
MURPHY USA INC.
MUSA